Interpace Diagnostics Joins the Fight Against Pancreatic Cancer at the Pittsburgh PurpleStride Event
The Pancreatic Cancer Action Network’s PurpleStride Events Raise Funds and Awareness for the Deadliest Major Cancer
PARSIPPANY, N.J., July 13, 2017 (GLOBE NEWSWIRE) -- Interpace Diagnostics (Nasdaq:IDXG) has joined the Pancreatic Cancer Action Network (PanCAN) to raise critical funds and awareness for pancreatic cancer through the Pittsburgh PurpleStride Event. Employees and their families have united to create Team Interpace with a goal of raising $5,000 to support PanCAN’s mission to advance research, support patients and create hope.
The Pittsburgh PurpleStride Event, a 5K walk, will take place on September 9th at the Northshore RiverFront Park. This community event is planned by volunteers of PanCAN and will pay tribute to loved ones who have succumbed to pancreatic cancer, as well as honor those who are currently fighting it.
“Our employees in Pittsburgh are dedicated to providing diagnostic insights to physicians and patients at risk for developing pancreatic cancer,” said Jack Stover, President and CEO of Interpace. “Our focus in helping these patients aligns well with the objectives of PanCAN, and we are proud to participate in this important cause,” he added.
As the leading pancreatic cancer organization, PanCAN is working to expedite progress, improve patient outcomes and double survival by 2020 through key initiatives like Precision PromiseSM and Know Your Tumor®. The PanCAN has raised more than $87 million for this cause through community events from 2008 to 2016.
This year, an estimated 53,670 Americans will be diagnosed with pancreatic cancer, and approximately 43,090 will die from the disease. The five-year survival rate for pancreatic cancer is just nine percent.
The Pittsburgh PurpleStride event aims to improve patient outcomes by raising significant funds for PanCAN this year.
To learn more about the Pancreatic Cancer Action Network or PanCAN and how you can make a difference, visit www.pancan.org.
About PancraGEN®
PancraGEN® is a pancreatic cyst molecular test that, by using a small sample of pancreatic cyst fluid, can aid in pancreatic cancer risk assessment. PancraGEN® is 90% accurate, according to clinical studies, enabling effective risk stratification of patients. Pancreatic cancer is often difficult to diagnose in early stages and typically spreads rapidly with signs and symptoms appearing when the cancer is significantly advanced. Because of this, and that complete surgical removal of the pancreas is not possible, pancreatic cancer is considered a leading cause of cancer deaths.
About Interpace Diagnostics Group, Inc.
Interpace Diagnostics is a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for better patient diagnosis and management. The Company currently has three commercialized molecular tests; PancraGEN® for the diagnosis and prognosis of pancreatic cancer; ThyGenX, for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay and ThyraMIR®, for the diagnosis of thyroid cancer utilizing a proprietary gene expression assay. Interpace Diagnostics' mission is to provide personalized medicine through molecular diagnostics and innovation to advance patient care based on rigorous science.
About the Pancreatic Cancer Action Network (PanCAN)
The Pancreatic Cancer Action Network (PanCAN) is accelerating the pace of research progress for one of the world’s deadliest cancers. With an urgent mission to improve outcomes for pancreatic cancer patients and double survival by 2020, the organization, founded in 1999, executes a bold and comprehensive strategy to Wage Hope through research, patient services, advocacy and community engagement. The organization’s visionary goals, world-class programs and services, extensive grassroots network, patient-focused outcomes and advisory board of scientific and medical leaders, provide the critical backdrop to help pancreatic cancer patients today and create transformational change for all patients in the future.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Company's future financial and operating performance. The Company has attempted to identify forward looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from those expressed or implied by any forward-looking statement. Known and unknown risks, uncertainties and other factors include, but are not limited to, the Company's ability to adequately finance the business, its ability to restructure its liabilities and other obligations, the market's acceptance of its molecular diagnostic tests, its ability to retain or secure reimbursement, its ability to secure additional business and generate higher profit margins through sales of its molecular diagnostic tests, in-licensing or other means, projections of future revenues, growth, gross profit and anticipated internal rate of return on investments and our ability to maintain our NASDAQ listing. Additionally, all forward-looking statements are subject to the risk factors detailed from time to time in the Company's filings with the SEC, including without limitation, the Annual Report on Form 10-K filed with the SEC on March 31, 2017 and the amendment on Form 10-K/A filed on April 28, 2017, the company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2017 filed with the SEC on May 12, 2017, and the company’s Registration Statement on Form S-1 (333-218140, the “registration statement”) initially filed with the SEC on May 22, 2017 . Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
Interpace Diagnostics Media Contact: Paul Kuntz RedChip paul@redchip.com 412-708-4590
Released July 13, 2017